Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy

SIMPLE SUMMARY: Patients with advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma have been known to respond to first-line tyrosine kinase inhibitor (TKI) treatment. However, a subgroup of patients are non-responsive to the treatment, with poor survival outcomes, and those w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lue, Kun-Han, Huang, Chun-Hou, Hsieh, Tsung-Cheng, Liu, Shu-Hsin, Wu, Yi-Feng, Chen, Yu-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773680/
https://www.ncbi.nlm.nih.gov/pubmed/35053473
http://dx.doi.org/10.3390/cancers14020309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773680/
https://www.ncbi.nlm.nih.gov/pubmed/35053473
http://dx.doi.org/10.3390/cancers14020309

Ejemplares similares